P5396 - Enhancing Personalized Treatment of Crohn’s Disease With Novel Targeted Therapies: Results of a Live/Virtual Live Medical Education Symposium and On-Demand E-Learning Program

Daniel Bonder, PhD¹, Meghan Coulehan, MPH, CHCP², Aisha Suhail, ², Emily Kitterman, ², Russell D. Cohen, MD³, Uma Mahadevan, MD, FACG⁴
1Answers in CME, New York City, NY; 2Answers in CME, New York, NY; 3University of Chicago Medicine, Chicago, IL; 4University of California San Francisco, San Francisco, CA

Introduction: Many patients with moderate-to-severe Crohn’s disease (CD) don’t respond or lose response to anti-TNF agents, underscoring the need for alternative targeted treatment options. As the number of available medications for the treatment of CD has increased, treatment personalization can be more challenging. Clinicians may lack experience and require guidance on customizing novel treatments to patients’ needs.

Methods: At an accredited 60-minute educational symposium held during Digestive Disease Week (DDW) 2024, two leading experts in inflammatory bowel disease presented the latest data and shared their clinical opinions about the roles of recently approved IL-23-targeted biologics and JAK inhibitors in personalizing the management of CD. The symposium was subsequently adapted as a 15-minute on-demand e-learning program. Pre- and post-test assessments were administered to determine the impact of the education on participants’ knowledge, competence, confidence, and intended behavior change.

Results: US-based academic and community gastroenterologists attended the symposium in person (n=103) or virtually (n=96). As of March 2025, n=3148 participated in the e-learning program. Aggregate data analysis from the on-demand program demonstrated 36% overall improvement from baseline in knowledge and competence. The greatest improvement was observed in relation to personalizing CD treatment. Notably, participants’ ability to outline personalized treatment strategies with novel targeted therapies increased by 61%. Following the education, 93% of participants reported an intention to change practice, especially with identifying patients who may benefit from novel targeted therapies. As participants reported treating 7-10 patients/week, it is estimated that these practice changes may impact >25,000 patient interactions. Similar trends were observed in the results from the DDW 2024 symposium.

Discussion: A live CME symposium and on-demand e-learning program were effective at significantly improving gastroenterologists’ ability to personalize the management of patients with moderate-to-severe CD. These outcomes suggest persisting educational needs among clinicians regarding optimal integration of novel targeted therapies in CD across diverse patient populations and complex clinical situations. These gaps can be targeted in future educational efforts.


Figure: Learning outcomes from a live CME symposium and on-demand e-learning program on personalizing treatment of Crohn's disease with novel IL-23-targeted biologics and JAK inhibitors.

Disclosures:
Daniel Bonder indicated no relevant financial relationships.
Meghan Coulehan indicated no relevant financial relationships.
Aisha Suhail indicated no relevant financial relationships.
Emily Kitterman indicated no relevant financial relationships.
Russell Cohen: Abbvie – Consultant, Speakers Bureau. Bausch Health – Consultant. BMS – Consultant. Eli lilly – Consultant. Genentech – Consultant. Gilead Sciences – Consultant. Johnson & Johnson – Consultant. Pfizer – Consultant. Takeda – Consultant.
Uma Mahadevan: Abbvie – Consultant. Boehringer Ingelheim – Consultant. Bristol Myers Squibb – Consultant. Celltrion Inc – Consultant. Enveda Biosciences – Consultant. Gilead Sciences – Consultant. Janssen Pharmaceuticals – Consultant. Lilly – Consultant. Merck – Advisory Committee/Board Member. Pfizer – Consultant. Protagonist Therapeutics – Consultant. Rani Therapeutics – Consultant. Roivant Sciences – Consultant. Takeda Pharmaceuticals USA – Consultant.

Daniel Bonder, PhD¹, Meghan Coulehan, MPH, CHCP², Aisha Suhail, ², Emily Kitterman, ², Russell D. Cohen, MD³, Uma Mahadevan, MD, FACG⁴. P5396 - Enhancing Personalized Treatment of Crohn’s Disease With Novel Targeted Therapies: Results of a Live/Virtual Live Medical Education Symposium and On-Demand E-Learning Program, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.